Effects of Anatolian Propolis and Hypertonic Saline Combination Nasal Spray on Allergic Rhinitis Symptoms: A Prospective, Multicenter Study

This prospective, multicenter observational study evaluated the efficacy of a nasal spray formulation—consisting of hypertonic saline combined with Anatolian propolis (brand: Rhinapi)—in patients with allergic rhinitis (AR). Between March 2022 and March 2023, approximately 10,000 patients (5,028 males, 4,972 females) across multiple centres in Turkey who exhibited nasal symptoms (discharge, sneezing, itching, obstruction) participated. Each patient self-administered one puff of the Rhinapi spray into each nostril three times daily for three weeks. Symptom severity (total symptom score), quality of life (QoL) scores, and otolaryngological examination findings (conchal colour and edema) were recorded before and after treatment. Results indicated a statistically significant improvement: mean total symptom score decreased from 11.09 ± 3.41 to 6.23 ± 2.41 (P < 0.001); mean QoL score improved from 6.44 ± 1.55 to 7.31 ± 1.24 (P < 0.001); and significant improvements were also observed in conchal colour and edema rating (P < 0.001). The authors conclude that the propolis-augmented hypertonic saline nasal spray can effectively reduce AR symptom burden and improve QoL, and may be recommended as an adjunctive treatment in allergic rhinitis.